RUA Life Sciences reaches positive adjusted EBITDA as Structural Heart spin-out reshapes the group

RUA Life Sciences has reached an important profitability milestone, although the headline profit figure requires careful interpretation.

In its trading update for the year ended 30 September 2026, released on 9 November 2026, the medical device group said revenue is expected to reach approximately £5.5 million. Adjusted EBITDA is expected to be positive at around £0.3 million.

That is encouraging progress for RUA Life Sciences PLC, but there are several moving parts. Biomaterials income exceeded budget following a royalty audit, while ABISS missed its revenue target and required additional funding. Meanwhile, most of the expected £4.7 million pre-tax profit comes from a non-recurring accounting gain linked to the RUA Structural Heart spin-out.

RUA Life Sciences' key figures

Metric	Year ended 30 September 2026	Comparison
Expected group revenue	Approximately £5.5 million	£5.1 million for the final 12 months of the previous 18-month reporting period
CDMO revenue	£2.8 million	Includes £2.4 million manufacturing and £0.4 million development revenue
ABISS revenue	£1.4 million	£1.9 million target
Biomaterials income	£1.0 million	Approximately 60% ahead of budget
Expected pre-tax profit	Approximately £4.7 million	Includes an approximately £4.8 million deconsolidation gain
Expected adjusted EBITDA	Approximately £0.3 million	Positive milestone
Expected year-end cash	Approximately £2.5 million	£3.2 million at 30 September 2025

Revenue growth calculation

Based on the figures supplied by the company, expected revenue growth was approximately 7.8%.

Calculation: (£5.5 million - £5.1 million) / £5.1 million = 7.8%.

This is my calculation using company-reported inputs, not company guidance beyond the underlying revenue figures.

The underlying business has moved into positive adjusted EBITDA

The most meaningful number in the update is arguably the expected £0.3 million of positive adjusted EBITDA. EBITDA means earnings before interest, tax, depreciation and amortisation, while the adjusted measure also removes specified non-cash and non-recurring items.

RUA describes this as an important milestone towards sustainable profitability. That wording matters. The group has reached positive adjusted EBITDA, but it has not claimed that sustainable profitability has already been secured.

The expected pre-tax profit of £4.7 million is less useful as a guide to underlying trading because it includes an approximately £4.8 million non-recurring gain following the loss of control of RUA Structural Heart.

Investors should therefore separate two developments:

• The operating businesses are expected to produce positive adjusted EBITDA of approximately £0.3 million.
• The reported pre-tax result is boosted by a large accounting gain that is not expected to recur.

That distinction prevents the headline profit from giving an overly flattering impression of ongoing earnings.

CDMO provides a foundation for recurring revenue

RUA's UK contract development and manufacturing operation, known as CDMO, generated total revenue of £2.8 million.

Commercial manufacturing contributed £2.4 million, in line with budget, while contract design and development added £0.4 million. The development work is particularly relevant because successful customer projects may convert into longer-term manufacturing agreements.

The group entered the year with agreed development proposals worth approximately £0.5 million. Work on these programmes has continued into the current financial year, although conversion into commercial manufacturing remains subject to successful project development.

The recently signed memorandum of understanding with an ABISS customer could also increase the scale of the Scottish manufacturing operation. Products currently manufactured in France are expected to transfer to Scotland, supported by the sale of some product intellectual property and financial assistance during the transition.

However, management says the new business will not arrive overnight because a regulatory process must be completed. That creates potentially attractive revenue visibility, but timing remains uncertain.

ABISS was the clear weak point

ABISS generated £1.4 million of revenue against a £1.9 million target. The £0.5 million shortfall followed inventory reductions by a major customer and a delayed resolution that was only achieved at the end of the financial period.

Instead of reaching its budgeted break-even position at the pre-tax level, ABISS is expected to report a £0.3 million loss. Its weaker trading also created approximately £0.3 million of additional internal funding requirements.

The new plan is to replace revenue transferring to Scotland by developing ABISS into a focused European pelvic floor device business with its own products. Progress includes appointing a distribution partner in a key European territory, recruiting an experienced product manager and agreeing in principle to become the European development partner for a pelvic floor repair product.

These are constructive steps, but they are early-stage commercial developments rather than proof that the lost manufacturing revenue has been replaced.

Biomaterials delivered an audit-related boost

Biomaterials income is expected to reach £1.0 million, approximately 60% ahead of budget.

The positive variance mainly came from historical underreported royalties identified through a customer audit. RUA also charged contractual interest on the missed royalties.

Royalty income is an important recurring stream, but investors should distinguish the continuing licensing economics from the catch-up element relating to previous underreporting. The update does not disclose how much of the £1.0 million relates to historical amounts or interest.

Structural Heart offers upside without the previous funding burden

During the year, RUA completed the spin-out financing for RUA Structural Heart. This included £3 million of external convertible loan funding and the capitalisation of £4.8 million of intercompany balances.

RUA Structural Heart is now an independent company and is no longer consolidated into the group accounts. RUA's ownership interest is instead treated as an investment.

Before the spin-out, RUA incurred £0.2 million of related costs. Since completion, the group has recognised £0.150 million of support-services revenue and £0.094 million of loan-note interest income.

Animal studies for the novel valve design are planned during 2027. Management believes successful testing could represent a significant value inflection point and support progress towards First in Man studies and future funding rounds. Success is not guaranteed, but RUA now retains potential investment upside without carrying the same ongoing research and development funding burden.

This builds on the strategic shift discussed in my earlier analysis of RUA Life Sciences' profitable transformation.

Cash remains the number to watch

Expected year-end cash was approximately £2.5 million, down from £3.2 million a year earlier but slightly above the £2.4 million reported at 31 March 2026.

My calculation puts the year-on-year reduction at approximately 21.9%: (£3.2 million - £2.5 million) / £3.2 million.

The company attributed the below-budget position mainly to weaker ABISS revenue and the timing of receipts from the royalty audit and research and development tax credits. Those amounts were still outstanding at year-end.

Timing effects may reverse when cash is collected, but the update does not disclose the amounts outstanding or when payment is expected. Investors will need the audited results to assess operating cash generation and working-capital movements properly.

What matters next for RUA investors

The positive case is that RUA has reached positive adjusted EBITDA, its core CDMO operation traded in line with budget, Biomaterials income was strong and Structural Heart is no longer creating the same funding drag.

The less comfortable side is that ABISS materially missed its target, cash declined year on year and the £4.7 million pre-tax profit is dominated by a one-off accounting gain.

Attention now turns to the transfer of French manufacturing to Scotland, the conversion of development programmes into recurring production contracts, ABISS's product-led strategy and the collection of outstanding cash receipts. RUA expects to publish audited results towards the end of January 2027, when investors should receive a fuller picture of underlying profitability and cash flow.